pyrroles has been researched along with fumarates in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| BRIDGER, WA; COHEN, LH | 1 |
| Abdellah, AT; Clark, AL; Cleland, JG; Coletta, AP; Khaleva, O | 1 |
| Bizot, MN; Camenisch, G; Dieterich, HA; Dole, WP; Howard, D; Reynolds, C; Schuetz, H; Vaidyanathan, S; Yeh, CM | 1 |
| Blankestijn, PJ; Joles, JA; Oey, PL; Siddiqi, L | 1 |
| Havekes, LM; Jukema, JW; Kühnast, S; Liau, G; Princen, HM; van den Hoek, AM; van der Hoorn, JW | 1 |
| Hadoke, PW | 1 |
| Arikawa, Y; Hamada, T; Hasuoka, A; Hirase, K; Hori, Y; Imanishi, A; Inatomi, N; Kajino, M; Kondo, M; Kurasawa, O; Matsukawa, J; Nishida, H; Takagi, T; Takeuchi, T; Tarui, N | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Chen, X; Li, M; Liu, A; Liu, Y; Luo, Z; Qiu, Y; Wang, G; Wang, H; Zhai, H; Zhang, H | 1 |
| Inatomi, N; Matsukawa, J; Nishida, H; Tsukimi, Y | 1 |
1 review(s) available for pyrroles and fumarates
| Article | Year |
|---|---|
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
1 trial(s) available for pyrroles and fumarates
| Article | Year |
|---|---|
Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Topics: Adult; Amides; Animals; Antifungal Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Female; Fumarates; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketoconazole; Male; Organic Anion Transporters; Pyrroles; Renin; Tissue Distribution; Young Adult | 2008 |
8 other study(ies) available for pyrroles and fumarates
| Article | Year |
|---|---|
STUDIES OF THE MECHANISM OF ACTION OF ADENYLOSUCCINASE.
Topics: Adenine Nucleotides; Adenylosuccinate Lyase; Catalysis; Copper; Enzyme Inhibitors; Fumarates; Lyases; Mercury; Mutation; Neurospora; Pyrroles; Research; Sulfhydryl Compounds; Sulfonic Acids | 1964 |
Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure.
Topics: Acute Disease; Amides; Atorvastatin; Cardiac Pacing, Artificial; Clinical Trials as Topic; Fumarates; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pulmonary Edema; Pyrroles; Renin; Respiration, Artificial | 2007 |
Atorvastatin reduces sympathetic activity in patients with chronic kidney disease.
Topics: Adult; Amides; Arteries; Atorvastatin; Blood Pressure; Case-Control Studies; Female; Fumarates; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Sympathetic Nervous System; Sympatholytics; Time Factors | 2011 |
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.
Topics: Amides; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Female; Fumarates; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles | 2012 |
Does the combination of a renin inhibitor with a statin have potential for improved inhibition of atherosclerosis?
Topics: Amides; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Female; Fumarates; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2012 |
Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).
Topics: Animals; Anti-Ulcer Agents; Dogs; Enzyme Inhibitors; Fumarates; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides | 2012 |
Development of a stability- indicating HPLC method for simultaneous determination of ten related substances in vonoprazan fumarate drug substance.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Cost-Benefit Analysis; Drug Contamination; Drug Stability; Fumarates; Limit of Detection; Oxidation-Reduction; Proton Pump Inhibitors; Pyrroles; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Technology, Pharmaceutical; Time Factors | 2018 |
[Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate].
Topics: Drug Evaluation, Preclinical; Fumarates; Humans; Potassium; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2018 |